Bulletin
Investor Alert

July 15, 2020, 6:15 a.m. EDT

Moderna stock surges 17% on coronavirus vaccine trial news

New study shows ‘robust’ immune response to trial vaccine, Moderna says

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Moderna Inc. (MRNA)
  • X
    S&P 500 Index (SPX)
  • X
    Dow Jones Industrial Average (DJIA)

or Cancel Already have a watchlist? Log In

By Claudia Assis, MarketWatch


Getty Images
Moderna headquarters in Cambridge, Mass.

Moderna Inc. stock skyrocketed in premarket trade Wednesday, after the biotech company said its coronavirus vaccine candidate produced a “robust” immune-system response in a larger group of people and the study will move to a decisive clinical trial in July.

Results published in The New England Journal of Medicine showed that a two-dose vaccination schedule induced the desired immune response in all 45 people evaluated, a larger group than in the preliminary data Moderna /zigman2/quotes/205619834/composite MRNA +0.46%  released in May, and was generally safe and well-tolerated, the company said.

Shares of Moderna already rallied after-hours Tuesday. The company is a front-runner among several developing experimental COVID-19 vaccines.

The results “reaffirm the positive interim data” released back in May, Moderna said. The trial vaccine “induced rapid and strong immune responses against SARS-CoV-2,” the coronavirus that causes COVID-19.

No serious adverse effects were reported, but some that did occur, such as headaches and fatigue, were “generally transient and mild to moderate in severity,” the company said.

Moderna is evaluating whether the participants’ immune responses are lasting, with participants followed for one year.

A Phase 3 study will start this month “to demonstrate our vaccine’s ability to significantly reduce the risk of COVID-19 disease,” Moderna said. It added that it remained on track “to be able to deliver approximately 500 million doses per year, and possibly up to 1 billion doses per year” beginning in 2021.

Moderna last week said it had signed another manufacturing deal for the investigational vaccine, this time with Spain’s Laboratorios Farmacéuticos Rovi. As part of the race for a coronavirus vaccine, drugmakers have scaled up their vaccine candidates’ production to hasten the time that it would take to distribute a working vaccine.

The new details about Moderna’s vaccine candidate emerged as Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said he was “cautiously optimistic” about a coronavirus vaccine relatively soon.

“We are in a pretty good place when it comes to a vaccine,” Fauci said at an event late Tuesday. “If things work out the way we hope they do,” a safe and effective vaccine would be ready for distribution by late 2020, beginning of 2021, he said. “I’m cautiously optimistic about that.”

Assuming that timetable is correct, the companies racing to develop a vaccine have promised that many doses will be available right away, Fauci said.

Shares of Moderna have nearly quadrupled this year, contrasting with losses around 1% and 7% for the S&P 500 index /zigman2/quotes/210599714/realtime SPX +0.06%  and the Dow Jones Industrial Average /zigman2/quotes/210598065/realtime DJIA +0.17%  in the same period.

/zigman2/quotes/205619834/composite
US : U.S.: Nasdaq
$ 74.10
+0.34 +0.46%
Volume: 8.77M
Aug. 7, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$28.81 billion
Rev. per Employee
$177,721
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,351.28
+2.12 +0.06%
Volume: 2.28B
Aug. 7, 2020 5:10p
loading...
/zigman2/quotes/210598065/realtime
US : Dow Jones Global
27,433.48
+46.50 +0.17%
Volume: 324.93M
Aug. 7, 2020 5:10p
loading...

Claudia Assis is a San Francisco-based reporter for MarketWatch. Follow her on Twitter @ClaudiaAssisMW.

Get news alerts on Moderna Inc. — or create your own.
This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.